A Study of Saruparib for High-Risk Prostate Cancer with a BRCA Mutation
This study is for men with high-risk prostate cancer that has a BRCA gene mutation. It's testing a drug called Saruparib against a placebo (an inactive pill) when added to standard treatments like radiation therapy (RT) and androgen deprivation therapy (ADT). Some participants will also receive Abiraterone and Prednisolone/Prednisone. The main goal is to see if Saruparib can help you live longer without the cancer spreading (metastasis-free survival). About 700 men will participate. The study is currently recruiting, but the exact status is unclear.
- Study design
- This is an interventional study where about 700 adult participants will be randomly assigned to receive either Saruparib or a placebo, along with standard treatments. Participants will be divided into two groups based on their prostate cancer diagnosis.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- All participants will be followed for survival until the end of the study, with metastasis-free survival measured for up to approximately 93 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06952803
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Recruiting
PHASE3Ages 18+InterventionalTreatmentAstraZeneca
~700 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:SaruparibPlaceboAbiraterone + Prednisolone/PrednisoneAndrogen Deprivation Therapy (ADT)
At a glance
Recruiting sites
261 of 346 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Metastasis-free survival (MFS)
Measured over Up to approximately 93 months
Conditions
Where it's being run
346 sites across 54 statesChina30
Germany24
France22
Italy18
United Kingdom16
Brazil15
Japan15
Spain14
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Male participants with a histologically documented diagnosis of prostate adenocarcinoma.
Newly diagnosed high-risk and very high-risk (localised/locally advanced) prostate cancer or a high-risk biochemical recurrence (BCR) following radical prostatectomy.
Provision of a formalin fixed and paraffin embedded (FFPE) tumour tissue sample.
Confirmed BRCA1 or BRCA2 mutation status by central tumour tissue is required for enrolment.
Participants required to have a computed tomography (CT) or magnetic resonance imaging (MRI) and a bone scan following the completion of their planned RT. This screening scan must confirm no evidence of disease or evidence of disease confined to the pelvis (M0).
Participants required to have a prostate-specific membrane antigen-positron emission tomography (PSMA-PET) following the completion of their planned RT. This screening scan must confirm no evidence of disease or evidence of disease confined to the pelvis (M0).
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration over the 2 weeks prior to randomization.
Minimum life expectancy of 12 months.
Adequate organ and bone marrow function as described in study protocol.
All participants will have received either primary or salvage RT. Participants must be eligible for randomisation within 10 months of initial diagnosis (de novo or BCR). Radiotherapy administered to the prostate (± pelvis) either in the primary or salvage setting must be delivered with curative intent. Use of metastases-directed therapy, as part of the RT radiation plan, is permitted as localised RT treatment for a metastatic lesion(s) outside the pelvis.
All participants will have received a planned regimen of ADT with a gonadotropin releasing hormone (GnRH) analogue.
Participants must not father children or donate sperm from signing informed consent form (ICF), during the study intervention and for 6 months after the last dose of study intervention.
Participants must use a condom (with spermicide - where permitted) from signing ICF, during study intervention, and for 6 months after the last dose of study drug, with all sexual partners.
Exclusion
Participants with a history of myelodysplastic syndrome (MDS)/ acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
Participants with any known predisposition to bleeding \[e.g., active peptic ulceration, recent (within 6 months) hemorrhagic stroke, proliferative diabetic retinopathy\].
Any history of persisting (\> 2 weeks) severe cytopenia due to any cause.
Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of saruparib and/or abiraterone.
History of another primary malignancy, with exceptions.
Persistent toxicities \[Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 2\] caused by previous anticancer therapy.
Cardiac criteria, including history of arrhythmia and cardiovascular disease.
Evidence of active and uncontrolled hepatitis B and/or hepatitis C.
Evidence of active and uncontrolled human immunodeficiency virus (HIV) infection.
Active tuberculosis infection.
Any prior chemotherapy (i.e., docetaxel) or immunotherapy; any prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor.
Prior treatment within 14 days with blood product support or growth factor support.
Concomitant use of strong inducers and inhibitors of CYP3A4 (applies to saruparib and abiraterone) or herbal supplements within 21 days or at least 5 half-lives (whichever is longer), of randomization.
Concomitant use of drugs that are known to prolong QT and have a known risk of Torsades de Pointes (TdP).
Participants with a known hypersensitivity to saruparib or any excipients of these products.
What this trial measures
- Metastasis-free survival (MFS)Up to approximately 93 months
MFS is defined as the time from randomisation until the date of first appearance of distant metastases, confirmed by standard clinical imaging \[computed tomography (CT)/ magnetic resonance imaging (MRI) and bone scan, or prostate-specific membrane antigen-positron emission tomography (PSMA-PET)\], as assessed by blinded independent central review (BICR) or death due to any cause.